Protara Reports Positive Phase 2 Data For TARA-002 In Bladder Cancer Study

Protara Therapeutics reported positive updated 12-month data from its Phase 2 ADVANCED-2 study of TARA-002 in patients with non-muscle invasive bladder cancer. The update is clinically encouraging for the program and may support further development of the therapy. The release is positive for the company, though it is still early-stage clinical data and likely to have only a limited near-term market impact.

Analysis

Protara Therapeutics reported positive updated 12-month data from its Phase 2 ADVANCED-2 study of TARA-002 in patients with non-muscle invasive bladder cancer. The update is clinically encouraging for the program and may support further development of the therapy. The release is positive for the company, though it is still early-stage clinical data and likely to have only a limited near-term market impact.